A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (NCT07169578)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 50 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (143 Sites)
Showing the first 25 of 143 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Banner Sun Health Research Institute — Sun City, Arizona
- Irvine Center for Clinical Research — Irvine, California
- Inglewood Clinicals — Los Angeles, California
- UCSF - Memory and Aging Center — San Francisco, California
- Syrentis Clinical Research — Santa Ana, California
- K2 Medical Research - The Villages — Lady Lake, Florida
- K2 Medical Research, LLC — Maitland, Florida
- Renstar Medical Research — Ocala, Florida
- Axiom Brain Health LLC — Tampa, Florida
- Charter Research - Lady Lake/The Villages — The Villages, Florida
- Alzheimer?s Research and Treatment Center — Wellington, Florida
- Conquest Research, LLC — Winter Park, Florida
- Alzheimer's Research and Treatment Center - Columbus — Columbus, Georgia
- Accel Research Sites-NeuroStudies — Decatur, Georgia
- Hawaii Pacific Neuroscience — Honolulu, Hawaii
- RE:Cognition (Chicago) — Chicago, Illinois
- Tandem Clinical Research, LLC — Marrero, Louisiana
- Brigham and Womens Hospital — Boston, Massachusetts
- Boston Center for Memory — Newton, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- The Cognitive and Research Center of New Jersey — Ridgewood, New Jersey
- Basil Clinical — Laurelton, New York
- Weill Cornell Medical College — New York, New York
- Adams Clinical Harlem — New York, New York
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimers Disease
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) — Birmingham, Alabama
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Atlantis, Florida
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Birmingham, Alabama
- A Post Authorization Registry Study of Participants Treated With LEQEMBI — Vancouver, British Columbia
- A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Phoenix, Arizona
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Birmingham, Alabama
Explore by condition: All Alzheimers Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.